Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

NDAQ:LMNL - Post Discussion

View:
Post by Steve33 on Jan 09, 2020 11:07am

Any news

This stock is so thinly traded that anybody that wants a position has to pay dearly for it. My belief is there is no impending news but anticipation of what is to come, is doing it. The plasminogen bla I would hope makes it this time or this company really does deserve to implode again and fall to its death. They would be as vigilant as possible this time and spare no expense to make this happen. When it does pass we will definitely be halted. After the halt it will be a multiple of what it is now. I just don't know what that number is. With the float and the unlocked potential I have to assume it will be over 100. I say that because IVIG will go ahead and all the other proteins as the mechanical process is the one thing holding us back from everything.
Comment by Transit77 on Jan 09, 2020 12:20pm
Let's assume all is accomplished? What is that potential upside 100,200,300 what is possible should they accomplish EVERYTHING???? $1000?????
Comment by marcjohnson on Jan 09, 2020 12:31pm
This post has been removed in accordance with Community Policy
Comment by Transit77 on Jan 09, 2020 12:36pm
ok a safe bet if between 150-250 ???? Should things pan out ???
Comment by StockReddy on Jan 09, 2020 12:57pm
My expectation is $60 to 80 that is equal to 1.5 to 2 billions market cap.
Comment by marcjohnson on Jan 09, 2020 12:57pm
This post has been removed in accordance with Community Policy
Comment by biotech1973 on Jan 09, 2020 12:56pm
If everything goes well and a partnership with upfront 50 Million for ryplazim. We should have 100 million in account by 4 months minus our burn and sales of 400 million a year. This can go to 2 billion cap plus minus 300 million. which is 100$ Maximum. Then if lazard closes PBI 4050 Partnership and We fast track PBi for Phase 3. This can go further 3 folds to 300-350$. But these are all ...more  
Comment by foofadooo on Jan 09, 2020 1:11pm
.......the amazing part is.......one country can bring that front money.....with 3000 indications identified.....where is the stop block......4050, 4547?.....we have a long rewarding road ahead of us ,, foof
Comment by foofadooo on Jan 09, 2020 12:56pm
.......it just reached the "dearly zone" ......a little bit above what those rights were exercised at.....the fruit of the tree can soon be picked.... the science is beyond belief in our world .... education and guts will make the day....GLTA....foof
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities